We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · May 22, 2014

SC vs IV Rituximab As Maintenance for Follicular Lymphoma

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Comparison of Subcutaneous Versus Intravenous Administration of Rituximab as Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
J. Clin. Oncol 2014 May 12;[EPub Ahead of Print], A Salar, I Avivi, B Bittner, R Bouabdallah, M Brewster, O Catalani, G Follows, A Haynes, F Hourcade-Potelleret, A Janikova, JF Larouche, C McIntyre, M Pedersen, J Pereira, P Sayyed, O Shpilberg, G Tumyan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading